Supernus Pharma To Report Phase III SPN-812 Data - Your Attention, Please

Supernus Pharmaceuticals Inc. (SUPN) is all set to report results from its two phase III studies of SPN-812 tomorrow, December 6, 2018, at approximately 7:00 a.m. ET.

from RTT - Biotech https://ift.tt/2PmxWod
via IFTTT